Dogwood Therapeutics Inc (DWTX)

Dogwood Therapeutics' stock price has underperformed, decreasing by 23.8% over the past six months and trading at $3.17. The company's shares have underperformed the S&P500 Index by -42.28% over the past six months. Shares were trading -41.64% below their 200-day moving average, with a last closing price of $2.98. A 1-for-25 reverse stock split occurred on October 9th, 2024. The company released its quarterly earnings data on November 6th, 2025, reporting an EPS of ($8.20), which missed the consensus estimate of ($1.23) by $6.97.

Information regarding the demand seasonality for Dogwood Therapeutics, Inc.'s products and services is not available. Demand is likely driven by clinical trial progress, regulatory approvals, and the prevalence of the diseases it aims to treat, rather than typical seasonal consumer patterns.

Dogwood Therapeutics, Inc. (DWTX) is a development-stage biotechnology company focused on discovering and advancing novel therapeutics for pain, neuropathy, and fatigue-related disorders. The company operates in the Medical sector, specifically in the Biomedicine/Genetics industry, with a focus on Pharmaceutical Products. The company, formerly known as Virios Therapeutics, Inc., was incorporated in 2012 and changed its name to Dogwood Therapeutics, Inc. in October 2024. Dogwood Therapeutics' research pipeline includes a non-opioid analgesic program and an antiviral program. IMC-1, a fixed-dose combination of famciclovir and celecoxib, has completed Phase 2b clinical trials for fibromyalgia. Halneuron®, a selective sodium channel blocker, is in Phase 2b clinical trials for chemotherapy-induced neuropathic pain (CINP) and cancer-related pain (CRP), and pre-clinical trials for burn and ocular pain. IMC-2, a combination of valacyclovir and celecoxib, is in Phase 2 clinical trials for long-COVID and post-acute sequelae of COVID-19 infection. Dogwood Therapeutics holds the rights to develop and commercialize SP16 IV, a low-density lipoprotein receptor related protein-1 (LRP1) agonist, for neuropathy and nerve damage prevention or repair following chemotherapy.

Dogwood Therapeutics, Inc. is based in Alpharetta, Georgia, United States, where its corporate offices are located.

Dogwood Therapeutics is classified as a "Sucker Stock" by Stockopedia based on its quality, value, and momentum. TradeSmith's Health Indicator places the company's financial health in the "Yellow zone," indicating a significant pullback but still within expected volatility, a status it has maintained for over a month.

Key individuals holding positions within Dogwood Therapeutics, Inc. include Greg Duncan (CEO and Chairman), William L. Pridgen (Founder and Director), Angela Walsh (Vice President of Finance, Treasurer), R. Michael Gendreau (Chief Medical Officer), and Ralph Grosswald (Vice President of Operations). Other directors include Abel De La Rosa, David Keefer, John C. Thomas, Jr., Richard Burch, and Richard J. Whitley.